Hello Flow Community, What are your observations in using flow cytometry to detect minimal residual disease in AML that does not have an aberrant T or B phenotype (ie no CD7, CD56, CD19 etc)? If your patient has various myeloid markers of various intensities, do you follow intensity as well as positive and negative? Also, what is your experience with CD117 absence after chemo when it was present at initial diagnosis. If the bone marrow specimen has only myeloid markers present vs having myeloid and B markers, does this mean anything? I would appreciate hearing from you. Thank you Bessie -- Bessie Kam Email: bkam@dls.queens.org The Queen's Medical Center, Pathology FAX: 808-547-4045 Phone: 808-547-4271Received on Fri Jan 28 09:38:00 2005
This archive was generated by hypermail 2.1.8 : Sat Jan 14 2006 - 22:03:34 EST
